Publications

Show Filters

Searches all publications.

Search Term

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

257318 items
12:00 AM, Sep 25, 1995  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

U.S. Bioscience Inc. (UBS) Business: Cancer Merrill Lynch analyst Richard Vietor said he expects the West Conshohocken, Penn., company's Ethyol to receive FDA marketing approval by year end, with a label to prevent cumulative...
12:00 AM, Sep 25, 1995  |  BC Week In Review | Clinical News  |  Regulatory

Pharmos regulatory update

PARS received notice of allowance for a U.S. patent covering submicron emulsions as an ocular drug delivery vehicle. The technology is particularly relevant to the formulation of non water-soluable drugs, the New York company said....
12:00 AM, Sep 25, 1995  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Biogen Inc. (BGEN) Business: Biopharmaceuticals Jeffrey Casdin of Merrill Lynch upgraded BGEN to "buy" from "above average," as an FDA advisory panel is likely to consider Avonex beta interferon for multiple sclerosis in December,...
12:00 AM, Sep 25, 1995  |  BC Week In Review | Company News  |  Deals

Somatogen, Eli Lilly deal

SMTG received a $2 million milestone payment from Lilly after completing enrollment in two Phase II trials of Optro (rHb1.1), SMTG's recombinant human hemoglobin product. The companies also amended their agreement in order to accelerate...
12:00 AM, Sep 25, 1995  |  BC Week In Review | Clinical News  |  Clinical Results

Viracept AG-1343 data

Pilot Phase II results of Viracept in 30 HIV-infected patients showed significant reductions in HIV levels detectable in blood in all patients. Subjects received one of three daily doses of a tablet formulation of AG-1343...
12:00 AM, Sep 18, 1995  |  BC Week In Review | Company News  |  Deals

PDT, Pharmacia S.p.A deal

The companies signed two supply contracts that will support their agreement under which Pharmacia acquired the rights to PDTI's tin ethyl etiopurpurin (SnET2) (see BioCentury, July 10). Under one agreement, the Santa Barbara, Calif., developer...
12:00 AM, Sep 18, 1995  |  BC Week In Review | Clinical News  |  Regulatory

Interneuron regulatory update

The Lexington, Mass., company said U.S. Patent No. 5,449,683 issued to the Massachusetts Institute of Technology covering the use of very low doses of melatonin to induce sleep. IPIC has a license to the patent....
12:00 AM, Sep 18, 1995  |  BC Week In Review | Company News  |  Other News

Cygnus drug delivery news

The Redwood City, Calif., company changed its name from Cygnus Therapeutics Systems to Cygnus Inc., and changed its state of incorporation to Delaware. The company's shares will continue to trade on NASDAQ under the...
12:00 AM, Sep 18, 1995  |  BC Week In Review | Clinical News  |  Clinical Results

Diastat rectal diazepam data

ATHN (South San Francisco) announced preliminary results from a second pivotal trial in 114 children and young adults, showing a statistically significant lowering of subsequent seizure rate. A seizure was suffered by 45 percent...
12:00 AM, Sep 18, 1995  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Guilford Pharmaceuticals Inc. (GLFD) Business: Neuroscience Oppenheimer & Co. analyst Matthew Geller initiated coverage of the Baltimore company and added it to OpCo's "recommended list." He said the company probably will receive FDA approval for...

Pages